Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic User Fees Have Four-Month Negotiating Window As Differences Narrow

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA calculates it that needs to reach an agreement with industry by June in order to have a proposal ready for Congress by early 2012.

You may also be interested in...



GDUFA Stakeholder Deadline Extended; Are Talks Delayed?

FDA says stakeholders who want to participate in monthly updates during formal generic drug user fee talks have until late April 2016 to give notice, prompting questions about the negotiation schedule.

ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point

The generics industry does not appear satisfied with an FDA proposal to treat all applications equally under a new generic drug user fee program, preferring instead to create another, separate user fee that would clear the ANDA application backlog faster.

ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point

The generics industry does not appear satisfied with an FDA proposal to treat all applications equally under a new generic drug user fee program, preferring instead to create another, separate user fee that would clear the ANDA application backlog faster.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel